Philip Ma Investment Reports Interview | CEO & Founder


Philip Ma, CEO & Founder, PrognomiQ

investment reports logo

PrognomiQ’s proprietary approach leverages cutting-edge technologies, including Seer’s Proteograph Product Suite, which enables collection of deep, unbiased proteomics data. In addition to proteomics, PrognomiQ interrogates the range of data from genotype to phenotype including cell-free DNA, RNA, metabolites, and lipids to identify potential biomarkers of significance. The combination of proteomic data with genomic, metabolomic, epigenomic, and transcriptomic data provides unparalleled levels of novel biological insights which could lead to transformative new approaches to diagnostic and therapy development.

Read the full article on Investment Reports here.

Share this page: